The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

A gene-editing therapy for sickle cell disease, with a price tag of £1.65m, is to be offered to patients on the NHS in England. About 50 people a year with the inherited blood disorder are likely to ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

One of the world’s most expensive medicines will be used to treat some patients with sickle cell disease in England using the state-funded National Health Service.Most Read from BloombergHow the 2025 ...

Nonetheless, gaining access to the Casgevy or Lyfgenia ... CMS intends to move the process forward by engaging all states that participate in the Medicaid Drug Rebate Program to help them decide ...

However, Casgevy is an ex vivo treatment, meaning patients’ cells are edited outside the body in the treatment process. Download the free BBJ app for important news alerts on your phone.